Caspase-6 and neurodegeneration

Trends in Neurosciences

Volumn 34, Issue 12, 2011, Pages 646-656

  Graham, Rona K ^a   Ehrnhoefer, Dagmar E ^a   Hayden, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CASPASE 2; CASPASE 3; CASPASE 6; CASPASE 8; HUNTINGTIN; LAMIN;

AGING; ALZHEIMER DISEASE; APOPTOSIS; BRAIN TISSUE; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; HUNTINGTON CHOREA; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; STROKE;

ALZHEIMER DISEASE; ANIMALS; CASPASE 6; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HUMANS; HUNTINGTON DISEASE; MODELS, MOLECULAR; NERVE DEGENERATION; PROTEIN CONFORMATION;

EID: 82855175119     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2011.09.001     Document Type: Review

References (142)

1. Baumgartner R., et al. The crystal structure of caspase-6, a selective effector of axonal degeneration. Biochem. J. 2009, 423:429-439.
2. Pop C., Salvesen G.S. Human caspases: activation, specificity, and regulation. J Biol. Chem. 2009, 284:21777-21781.
3. Thornberry N.A., et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 1997, 272:17907-17911.
4. Fischer U., et al. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ. 2003, 10:76-100.
5. Nicholson D.W. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 1999, 6:1028-1042.
6. Troy C.M., et al. Regulation of caspases in the nervous system implications for functions in health and disease. Prog. Mol. Biol. Transl. Sci. 2011, 99:265-305.
7. Troy C.M., Salvesen G.S. Caspases on the brain. J. Neurosci. Res. 2002, 69:145-150.
8. Friedlander R.M. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 2003, 348:1365-1375.
9. Riedl S.J., Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol. 2004, 5:897-907.
10. Albrecht S., et al. Activation of caspase-6 in aging and mild cognitive impairment. Am. J. Pathol. 2007, 170:1200-1209.
11. Guo H., et al. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am. J. Pathol. 2004, 165:523-531.
12. Graham R.K., et al. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. J. Neurosci. 2010, 30:15019-15029.
13. Singh A.B., et al. Cloning and expression of rat caspase-6 and its localization in renal ischemia/reperfusion injury. Kidney Int. 2002, 62:106-115.
14. Fernandes-Alnemri T., et al. Mch2, a new member of the apoptotic Ced-3/Ice cysteine protease gene family. Cancer Res. 1995, 55:2737-2742.
15. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 1997, 326:1-16.
16. Van de Craen M., et al. The proteolytic procaspase activation network: an in vitro analysis. Cell Death Differ. 1999, 6:1117-1124.
17. Slee E.A., et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol. 1999, 144:281-292.
18. Cowling V., Downward J. Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death Differ. 2002, 9:1046-1056.
19. Xanthoudakis S., et al. Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis. EMBO J. 1999, 18:2049-2056.
20. Allsopp T.E., et al. Caspase 6 activity initiates caspase 3 activation in cerebellar granule cell apoptosis. Cell Death Differ. 2000, 7:984-993.
21. Liu X., et al. Purification and characterization of an interleukin-1beta-converting enzyme family protease that activates cysteine protease P32 (CPP32). J. Biol. Chem. 1996, 271:13371-13376.
22. Henshall D.C., et al. Expression and differential processing of caspases 6 and 7 in relation to specific epileptiform EEG patterns following limbic seizures. Neurobiol. Dis. 2002, 10:71-87.
23. Ferrer I., et al. Differential c-Fos and caspase expression following kainic acid excitotoxicity. Acta Neuropathol. 2000, 99:245-256.
24. Graham R.K., et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
25. Hermel E., et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ. 2004, 11:424-438.
26. Pouladi M.A., et al. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 2009, 132:919-932.
27. Milnerwood A.J., et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010, 65:178-190.
28. Warby S.C., et al. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum. Mol. Genet. 2008, 17:2390-2404.
29. Gervais F.G., et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 1999, 97:395-406.
30. Galvan V., et al. Caspase cleavage of members of the amyloid precursor family of proteins. J. Neurochem. 2002, 82:283-294.
31. Zhao M., et al. Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer's disease. Neurobiol. Dis. 2003, 14:391-403.
32. Lu D.C., et al. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat. Med. 2000, 6:397-404.
33. Saganich M.J., et al. Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. J. Neurosci. 2006, 26:13428-13436.
34. Nguyen T.V., et al. Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664. J. Neurochem. 2008, 104:1065-1080.
35. Galvan V., et al. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:7130-7135.
36. Park K.J., et al. p75NTR-dependent, myelin-mediated axonal degeneration regulates neural connectivity in the adult brain. Nat. Neurosci. 2010, 13:559-566.
37. +-sensitive pathway in insects and mammals. J. Neurosci. 2010, 30:6375-6386.
38. Nikolaev A., et al. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457:981-989.
39. Dash P.K., et al. Caspase activity plays an essential role in long-term memory. Neuroreport 2000, 11:2811-2816.
40. Bravarenko N.I., et al. Caspase-like activity is essential for long-term synaptic plasticity in the terrestrial snail Helix. Eur. J. Neurosci. 2006, 23:129-140.
41. Li Z., et al. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Cell 2010, 141:859-871.
42. Okouchi M., et al. Neuronal apoptosis in neurodegeneration. Antioxid. Redox Signal. 2007, 9:1059-1096.
43. Akpan N., et al. Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke. J. Neurosci. 2011, 31:8894-8904.
44. Albrecht S., et al. Caspase-6 activation in familial Alzheimer disease brains carrying amyloid precursor protein or presenilin I or presenilin II mutations. J. Neuropathol. Exp. Neurol. 2009, 68:1282-1293.
45. Novak M.J., Tabrizi S.J. Huntington's disease. Br. Med. J. 2010, 340:c3109.
46. Wellington C.L., et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 2002, 22:7862-7872.
47. Vis J.C., et al. Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathol. 2005, 109:321-328.
48. Kiechle T., et al. Cytochrome c and caspase-9 expression in Huntington's disease. Neuromol. Med. 2002, 1:183-195.
49. Wellington C.L., et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem. 2000, 275:19831-19838.
50. Mangiarini L., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
51. Hackam A.S., et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J. Cell Biol. 1998, 141:1097-1105.
52. Metzler M., et al. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J. Neurosci. 2010, 30:14318-14329.
53. Hodges A., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 2006, 15:965-977.
54. Tebbenkamp A.T., et al. Transgenic mice expressing caspase-6 derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative. Hum. Mol. Genet. 2011, 20:2770-2782.
55. Cepeda C., et al. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 2001, 66:525-539.
56. Okamoto S., et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 2009, 15:1407-1413.
57. Graham R.K., et al. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J. Neurosci. 2009, 29:2193-2204.
58. Beal M.F., et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986, 321:168-171.
59. Sanberg P.R., et al. Human fetal striatal transplantation in an excitotoxic lesioned model of Huntington's disease. Ann. N.Y. Acad. Sci. 1997, 831:452-460.
60. Kruman I., et al. Calcium and reactive oxygen species mediate staurosporine-induced mitochondrial dysfunction and apoptosis in PC12 cells. J. Neurosci. Res. 1998, 51:293-308.
61. Zhang G., et al. Isoflurane-induced caspase-3 activation is dependent on cytosolic calcium and can be attenuated by memantine. J. Neurosci. 2008, 28:4551-4560.
62. MacLachlan T.K., el Deiry W.S. Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:9492-9497.
63. Culmsee C., et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J. Neurochem. 2001, 77:220-228.
64. Liang Z.Q., et al. Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity. Neurobiol. Dis. 2005, 20:562-573.
65. Morrison R.S., et al. Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death. J. Neurosci. 1996, 16:1337-1345.
66. Zeron M.M., et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860.
67. Kim M., et al. Forskolin and dopamine D1 receptor activation increase huntingtin's association with endosomes in immortalized neuronal cells of striatal origin. Neuroscience 1999, 89:1159-1167.
68. Chen M., et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 2000, 6:797-801.
69. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
70. Zuccato C., et al. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90:905-981.
71. Pompl P.N., et al. Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease. Arch. Neurol. 2003, 60:369-376.
72. de Calignon A., et al. Caspase activation precedes and leads to tangles. Nature 2010, 464:1201-1204.
73. Rissman R.A., et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin. Invest. 2004, 114:121-130.
74. Gamblin T.C., et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10032-10037.
75. Klaiman G., et al. Targets of caspase-6 activity in human neurons and Alzheimer disease. Mol. Cell. Proteomics 2008, 7:1541-1555.
76. Banwait S., et al. C-Terminal cleavage of the amyloid-beta protein precursor at Asp664: a switch associated with Alzheimer's disease. J. Alzheimers Dis. 2008, 13:1-16.
77. Harris J.A., et al. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J. Neurosci. 2010, 30:372-381.
78. Sternberg C., et al. Caspase dependence of the death of neonatal retinal ganglion cells induced by axon damage and induction of autophagy as a survival mechanism. Braz. J. Med. Biol. Res. 2010, 43:950-956.
79. Monnier P.P., et al. Involvement of caspase-6 and caspase-8 in neuronal apoptosis and the regenerative failure of injured retinal ganglion cells. J. Neurosci. 2011, 31:10494-10505.
80. Su J.H., et al. Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology. Brain Res. 2001, 898:350-357.
81. LeBlanc A., et al. Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease. J. Biol. Chem. 1999, 274:23426-23436.
82. D'Amelio M., et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat. Neurosci. 2011, 14:69-76.
83. Kuida K., et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 1996, 384:368-372.
84. Houde C., et al. Caspase-7 expanded function and intrinsic expression level underlies strain-specific brain phenotype of caspase-3-null mice. J. Neurosci. 2004, 24:9977-9984.
85. Jiang C.H., et al. The effects of aging on gene expression in the hypothalamus and cortex of mice. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:1930-1934.
86. Friedlander R.M., Yuan J. ICE, neuronal apoptosis and neurodegeneration. Cell Death Differ. 1998, 5:823-831.
87. Harrison D.C., et al. Caspase mRNA expression in a rat model of focal cerebral ischemia. Brain Res. Mol. Brain Res. 2001, 89:133-146.
88. Hirata H., et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J. Exp. Med. 1998, 187:587-600.
89. Orth K., et al. The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol. Chem. 1996, 271:16443-16446.
90. Levkau B., et al. Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-kappa B loop. Nat. Cell Biol. 1999, 1:227-233.
91. Galande S., et al. SATB1 cleavage by caspase 6 disrupts PDZ domain-mediated dimerization, causing detachment from chromatin early in T-cell apoptosis. Mol. Cell Biol. 2001, 21:5591-5604.
92. Nyormoi O., et al. Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells. Mol. Cell Biol. 2001, 21:4856-4867.
93. Rouaux C., et al. Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochem. Pharmacol. 2004, 68:1157-1164.
94. Mazars A., et al. A caspase-dependent cleavage of CDC25A generates an active fragment activating cyclin-dependent kinase 2 during apoptosis. Cell Death. Differ. 2009, 16:208-218.
95. Chan Y.W., et al. Generation of an indestructible cyclin B1 by caspase-6-dependent cleavage during mitotic catastrophe. Oncogene 2009, 28:170-183.
96. Halawani D., et al. Identification of caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimer's disease: a novel link to dysfunction in ubiquitin proteasome system-mediated protein degradation. J. Neurosci. 2010, 30:6132-6142.
97. Graham R.K., et al. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol. Dis. 2006, 21:444-455.
98. Slow E.J., et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11402-11407.
99. Slow E.J., et al. To be or not to be toxic: aggregations in Huntington and Alzheimer disease. Trends Genet. 2006, 22:408-411.
100. Nakai M., et al. NMDA and non-NMDA receptor-stimulated IkappaB-alpha degradation: differential effects of the caspase-3 inhibitor DEVD.CHO, ethanol and free radical scavenger OPC-14117. Brain Res. 2000, 859:207-216.
101. Clemens J.A., et al. Global ischemia activates nuclear factor-kappa B in forebrain neurons of rats. Stroke 1997, 28:1073-1080.
102. Qin Z.H., et al. Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. J. Neurosci. 1999, 19:4023-4033.
103. Norman J.M., et al. The in vitro cleavage of the hAtg proteins by cell death proteases. Autophagy 2010, 6:1042-1056.
104. Rohn T.T., et al. Depletion of beclin-1 due to proteolytic cleavage by caspases in the Alzheimer's disease brain. Neurobiol. Dis. 2011, 43:68-78.
105. Pickford F., et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J. Clin. Invest. 2008, 118:2190-2199.
106. Panagopoulou P., et al. Desmin mediates TNF-alpha-induced aggregate formation and intercalated disk reorganization in heart failure. J. Cell Biol. 2008, 181:761-775.
107. Petrilli V., et al. Noncleavable poly(ADP-ribose) polymerase-1 regulates the inflammation response in mice. J. Clin. Invest. 2004, 114:1072-1081.
108. Kang B.H., et al. The structure of procaspase 6 is similar to that of active mature caspase 6. Biochem. J. 2002, 364:629-634.
109. Wang X.J., et al. Crystal structures of human caspase 6 reveal a new mechanism for intramolecular cleavage self-activation. EMBO Rep. 2010, 11:841-847.
110. Klaiman G., et al. Self-activation of caspase-6 in vitro and in vivo: caspase-6 activation does not induce cell death in HEK293T cells. Biochim. Biophys. Acta 2009, 1793:592-601.
111. Chai J., et al. Crystal structure of a procaspase-7 zymogen: mechanisms of activation and substrate binding. Cell 2001, 107:399-407.
112. Lee A.W., et al. Alternatively spliced caspase-6b isoform inhibits the activation of caspase-6a. J. Biol. Chem. 2010, 285:31974-31984.
113. Narkilahti S., Pitkanen A. Caspase 6 expression in the rat hippocampus during epileptogenesis and epilepsy. Neuroscience 2005, 131:887-897.
114. McStay G.P., et al. Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways. Cell Death Differ. 2008, 15:322-331.
115. Kilic M., et al. Formation of noncanonical high molecular weight caspase-3 and -6 complexes and activation of caspase-12 during serum starvation induced apoptosis in AKR-2B mouse fibroblasts. Cell Death Differ. 2002, 9:125-137.
116. Festjens N., et al. Caspase-containing complexes in the regulation of cell death and inflammation. Biol. Chem. 2006, 387:1005-1016.
117. Guo H., et al. Caspase-1 activation of caspase-6 in human apoptotic neurons. Cell Death Differ. 2006, 13:285-292.
118. Srinivasula S.M., et al. The Ced-3/interleukin 1beta converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2alpha are substrates for the apoptotic mediator CPP32. J Biol. Chem. 1996, 271:27099-27106.
119. Dick O., Bading H. Synaptic activity and nuclear calcium signaling protect hippocampal neurons from death signal-associated nuclear translocation of FoxO3a induced by extrasynaptic N-methyl-D-aspartate receptors. J Biol. Chem. 2010, 285:19354-19361.
120. Zhang S.J., et al. Decoding NMDA receptor signaling: identification of genomic programs specifying neuronal survival and death. Neuron 2007, 53:549-562.
121. Bordji K., et al. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-β production. J. Neurosci. 2010, 30:15927-15942.
122. Lau D., Bading H. Synaptic activity-mediated suppression of p53 and induction of nuclear calcium-regulated neuroprotective genes promote survival through inhibition of mitochondrial permeability transition. J. Neurosci. 2009, 29:4420-4429.
123. Himeji D., et al. Characterization of caspase-8L: a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade. Blood 2002, 99:4070-4078.
124. Alnemri E.S., et al. Cloning and expression of four novel isoforms of human interleukin-1 beta converting enzyme with different apoptotic activities. J. Biol. Chem. 1995, 270:4312-4317.
125. Deveraux Q.L., et al. X-Linked IAP is a direct inhibitor of cell-death proteases. Nature 1997, 388:300-304.
126. Deveraux Q.L., et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998, 17:2215-2223.
127. Eckelman B.P., Salvesen G.S. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J. Biol. Chem. 2006, 281:3254-3260.
128. Hui K.K., et al. Caspase-3 deficiency reveals a physiologic role for Smac/DIABLO in regulating programmed cell death. Cell Death Differ. 2011, 18:1780-1790.
129. Tounekti O., et al. Proteasomal degradation of caspase-6 in 17beta-estradiol-treated neurons. J. Neurochem. 2004, 89:561-568.
130. Suzuki A., et al. Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene 2004, 23:7067-7075.
131. Kurokawa M., Kornbluth S. Caspases and kinases in a death grip. Cell 2009, 138:838-854.
132. Benjannet S., et al. Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J Biol. Chem. 2001, 276:10879-10887.
133. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
134. Lee D., et al. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J. Biol. Chem. 2000, 275:16007-16014.
135. Wannamaker W., et al. (S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J. Pharmacol. Exp. Ther. 2007, 321:509-516.
136. Leyva M.J., et al. Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models. Chem. Biol. 2010, 17:1189-1200.
137. Chu W., et al. Synthesis and in vitro evaluation of sulfonamide isatin Michael acceptors as small molecule inhibitors of caspase-6. J. Med. Chem. 2009, 52:2188-2191.
138. Ross J., et al. A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat. Neuropharmacology 2007, 53:638-642.
139. Ona V.O., et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999, 399:263-267.
140. Warby S.C., et al. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum. Mol. Genet. 2005, 14:1569-1577.
141. Warby S.C., et al. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol. Cell Neurosci. 2009, 40:121-127.
142. Porollo A., Meller J. Versatile annotation and publication quality visualization of protein complexes using POLYVIEW-3D. BMC Bioinformatics 2007, 8:316.